Position in JANX
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$1,252,403
-$4,064,750 QoQ
Shares Held
90,101
-76.6% QoQ
Ownership
0.148%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in JANX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026FRANKLIN RESOURCES INC holds $7,057,408,835 across 166 Biotechnology names. JANX ranks #114 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,722,071 | $2,103,180,930 | |
| 2 | ASND |
Ascendis Pharma A/S
|
2,051,948 | $469,342,063 | |
| 3 | INSM |
INSMED Inc
|
2,617,251 | $427,972,880 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
1,958,940 | $370,337,604 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
551,132 | $246,102,477 | |
| 6 | BBIO |
BridgeBio Pharma, Inc.
|
2,438,925 | $181,114,568 | |
| 7 | ARGX |
Argenx SE
|
233,493 | $170,508,261 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
470,390 | $155,637,935 |
All Filings in JANX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,252,403 | 90,101 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $5,317,153 | 385,301 | Shares | Defined | 2026-02-11 | |
| 2025-09-30 | $21,696,731 | 887,755 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $24,698,403 | 1,069,195 | Shares | Defined | 2025-08-12 | |
| 2025-03-31 | $32,034,933 | 1,186,479 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $26,624,744 | 497,287 | Shares | Defined | 2025-02-12 | |
| 2024-09-30 | $862,397 | 18,983 | Shares | Defined | 2024-11-27 | |
| 2024-06-30 | $483,452 | 11,541 | Shares | Defined | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||